RegeneRx Biopharmaceuticals, Inc. (RGRX)
RegeneRx Biopharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Rockville, MD, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $1,048. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -2249.8%. Its beta of 4.73 implies it has historically moved more than the broad market.
RegeneRx Biopharmaceuticals, Inc. is a biotechnology firm dedicated to the advancement of therapeutic peptides, with a primary emphasis on thymosin beta 4, engineered for the protection, repair, and regeneration of tissues and organs. The company's development pipeline includes RGN-259, a preservative-free ophthalmic solution designed to restore corneal tissues following injury, disease, or other pathologies; RGN-352, an injectable formulation under investigation for its potential in treating cardiovascular ailments, central and peripheral nervous system disorders, and various other medical conditions; and RGN-137, a topical gel aimed at accelerating the healing of skin wounds and minimizing scar tissue. Strategic alliances have been forged with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. Incorporated in 1982, the company initially operated as Alpha 1 Biomedicals, Inc., adopting the name RegeneRx Biopharmaceuticals, Inc. in 2000. Its operations are headquartered in Rockville, Maryland.
RegeneRx Biopharmaceuticals, Inc. is most often compared with the following Healthcare names: